## **Oliver W Hakenberg**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11503294/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	EAU Guidelines on Penile Cancer: 2014 Update. European Urology, 2015, 67, 142-150.	1.9	479
2	Perioperative Complications of Radical Cystectomy in a Contemporary Series. European Urology, 2007, 51, 397-402.	1.9	244
3	Lymphadenectomy in the Surgical Management of Penile Cancer. European Urology, 2009, 55, 1075-1088.	1.9	201
4	Prevention and Management of Complications Following Radical Cystectomy for Bladder Cancer. European Urology, 2010, 57, 983-1001.	1.9	194
5	Urine Markers for Detection and Surveillance of Non–Muscle-Invasive Bladder Cancer. European Urology, 2011, 60, 484-492.	1.9	176
6	Bladder wall thickness in normal adults and men with mild lower urinary tract symptoms and benign prostatic enlargement. Neurourology and Urodynamics, 2000, 19, 585-593.	1.5	146
7	Follow-up After Surgical Treatment of Bladder Cancer: A Critical Analysis of the Literature. European Urology, 2012, 62, 290-302.	1.9	121
8	Laparoscopic Living-Donor Nephrectomy: Analysis of the Existing Literature. European Urology, 2010, 58, 498-509.	1.9	119
9	Cisplatin, methotrexate and bleomycin for treating advanced penile carcinoma. BJU International, 2006, 98, 1225-1227.	2.5	105
10	The Estimation of Bladder Volume by Sonocystography. Journal of Urology, 1983, 130, 249-251.	0.4	100
11	Alterations in the tumor suppressor gene p16 INK4A are associated with aggressive behavior of penile carcinomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2011, 458, 221-229.	2.8	90
12	Expression of p53, p21 and cyclin D1 in penile cancer: p53 predicts poor prognosis. Journal of Clinical Pathology, 2012, 65, 232-236.	2.0	69
13	p16 <sup>INK4a</sup> is a Marker of Good Prognosis for Primary Invasive Penile Squamous Cell Carcinoma: A Multi-Institutional Study. Journal of Urology, 2012, 187, 899-907.	0.4	68
14	Risks and Benefits of Adjuvant Radiotherapy After Inguinal Lymphadenectomy in Node-positive Penile Cancer: A Systematic Review by the European Association of Urology Penile Cancer Guidelines Panel. European Urology, 2018, 74, 76-83.	1.9	61
15	Penile Sparing Surgery for Penile Cancer: A Multicenter International Retrospective Cohort. Journal of Urology, 2018, 199, 1233-1237.	0.4	59
16	Chemosensitization of bladder cancer cells by survivin-directed antisense oligodeoxynucleotides and siRNA. Cancer Letters, 2006, 232, 243-254.	7.2	50
17	Qualitative and quantitative assessment of urinary cytokeratin 8 and 18 fragments compared with voided urine cytology in diagnosis of bladder carcinoma. Urology, 2004, 64, 1121-1126.	1.0	47
18	Surgical management of penile carcinoma <i>in situ</i> : results from an international collaborative study and review of the literature. BJU International, 2018, 121, 393-398.	2.5	45

#	Article	IF	CITATIONS
19	Does Evaluation With the International Prostate Symptom Score Predict the Outcome of Transurethral Resection of the Prostate?. Journal of Urology, 1997, 158, 94-99.	0.4	43
20	Pharmacodynamics of propiverine and three of its main metabolites on detrusor contraction. British Journal of Pharmacology, 2005, 145, 608-619.	5.4	42
21	Is There a Relationship between the Amount of Tissue Removed at Transurethral Resection of the Prostate and Clinical Improvement in Benign Prostatic Hyperplasia. European Urology, 2001, 39, 412-417.	1.9	41
22	Propiverine and metabolites: differences in binding to muscarinic receptors and in functional models of detrusor contraction. Naunyn-Schmiedeberg's Archives of Pharmacology, 2006, 374, 87-97.	3.0	41
23	Contribution of Ca2+ influx to carbachol-induced detrusor contraction is different in human urinary bladder compared to pig and mouse. European Journal of Pharmacology, 2007, 565, 180-189.	3.5	40
24	CHOLINERGIC AND PURINERGIC RESPONSES IN ISOLATED HUMAN DETRUSOR IN RELATION TO AGE. Journal of Urology, 2005, 173, 2182-2189.	0.4	39
25	Comparative Diagnostic Value of Urine Cytology, UBC-ELISA, and Fluorescence In Situ Hybridization for Detection of Transitional Cell Carcinoma of Urinary Bladder in Routine Clinical Practice. Urology, 2007, 70, 449-453.	1.0	38
26	Clinical Outcomes of Perioperative Chemotherapy in Patients With Locally Advanced Penile Squamous-Cell Carcinoma: Results of a Multicenter Analysis. Clinical Genitourinary Cancer, 2017, 15, 548-555.e3.	1.9	37
27	Management of Germ Cell Tumours of the Testis in Adult Patients. German Clinical Practice Guideline Part I: Epidemiology, Classification, Diagnosis, Prognosis, Fertility Preservation, and Treatment Recommendations for Localized Stages. Urologia Internationalis, 2021, 105, 169-180.	1.3	37
28	Detailed Analysis of Charlson Comorbidity Score as Predictor of Mortality After Radical Prostatectomy. Urology, 2008, 72, 1252-1257.	1.0	34
29	Evidence from the â€ <sup>-</sup> PROspective MulticEnTer RadIcal Cystectomy Series 2011 (PROMETRICS 2011)â€ <sup>™</sup> Study: How are Preoperative Patient Characteristics Associated with Urinary Diversion Type After Radical Cystectomy for Bladder Cancer?. Annals of Surgical Oncology, 2015, 22, 1032-1042.	1.5	33
30	Spontaneous late rupture of orthotopic detubularized ileal neobladders: report of five cases. Urology, 2001, 58, 43-46.	1.0	30
31	Prognostic and diagnostic implications of epithelial cell adhesion/activating molecule ( <scp>EpCAM</scp> ) expression in renal tumours: a retrospective clinicopathological study of 948 cases using tissue microarrays. BJU International, 2014, 114, 296-302.	2.5	29
32	Influence of Body Mass Index on Clinical Outcome Parameters, Complication Rate and Survival after Radical Cystectomy: Evidence from a Prospective European Multicentre Study. Urologia Internationalis, 2018, 101, 16-24.	1.3	28
33	lssues in the Treatment of Penile Carcinoma. Urologia Internationalis, 1999, 62, 229-233.	1.3	27
34	Decreased Overall and Bladder Cancer–Specific Mortality with Adjuvant Chemotherapy After Radical Cystectomy: Multivariable Competing Risk Analysis. European Urology, 2016, 69, 984-987.	1.9	27
35	Nomogram-based prediction of overall survival after regional lymph node dissection and the role of perioperative chemotherapy in penile squamous cell carcinoma: A retrospective multicenter study. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 531.e7-531.e15.	1.6	27
36	Feasibility and Limitations of Comorbidity Measurement in Patients Undergoing Radical Prostatectomy. European Urology, 2005, 47, 190-195.	1.9	26

#	Article	IF	CITATIONS
37	Integrated Loss of miR-1/miR-101/miR-204 Discriminates Metastatic from Nonmetastatic Penile Carcinomas and Can Predict Patient Outcome. Journal of Urology, 2016, 196, 570-578.	0.4	26
38	Laser ablation as monotherapy for penile squamous cell carcinoma: A multi-center cohort analysis. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 147-152.	1.6	26
39	Which patients are at the highest risk of dying from competing causes â‰⊉O years after radical prostatectomy?. BJU International, 2012, 110, 206-210.	2.5	24
40	Chemotherapy in penile cancer. Therapeutic Advances in Urology, 2012, 4, 133-138.	2.0	23
41	Locally Recurrent Malignant Fibrous Histiocytoma: A Rare and Aggressive Genitourinary Malignancy. Urologia Internationalis, 1999, 62, 164-170.	1.3	22
42	Kiâ€67, miniâ€chromosome maintenance 2 protein ( <scp>MCM2</scp> ) and geminin have no independent prognostic relevance for cancerâ€specific survival in surgically treated squamous cell carcinoma of the penis. BJU International, 2013, 112, E383-90.	2.5	22
43	Inherent Grading Characteristics of Individual Pathologists Contribute to Clinically and Prognostically Relevant Interobserver Discordance Concerning Broders' Grading of Penile Squamous Cell Carcinomas. Urologia Internationalis, 2013, 90, 207-213.	1.3	22
44	Association Between Human Papillomavirus Infection and Outcome of Perioperative Nodal Radiotherapy for Penile Carcinoma. European Urology Oncology, 2021, 4, 802-810.	5.4	22
45	Effect of Hospital and Surgeon Case Volume on Perioperative Quality of Care and Short-term Outcomes After Radical Cystectomy for Muscle-invasive Bladder Cancer: Results From a European Tertiary Care Center Cohort. Clinical Genitourinary Cancer, 2017, 15, e809-e817.	1.9	21
46	Periâ€operative allogeneic blood transfusion does not adversely affect oncological outcomes after radical cystectomy for urinary bladder cancer: a propensity scoreâ€weighted European multicentre study. BJU International, 2018, 121, 101-110.	2.5	21
47	Relationship of Comorbidity, Age and Perioperative Complications in Patients Undergoing Radical Prostatectomy. Urologia Internationalis, 2001, 67, 283-288.	1.3	20
48	Effect of rilmakalim on detrusor contraction in the presence and absence of urothelium. Naunyn-Schmiedeberg's Archives of Pharmacology, 2005, 372, 203-212.	3.0	20
49	Molecular Therapy in Urologic Oncology. Urologia Internationalis, 2007, 79, 1-7.	1.3	20
50	Optimal treatment of locally advanced prostate cancer. World Journal of Urology, 2007, 25, 169-176.	2.2	20
51	Systematic Assessment of Complications and Outcome of Radical Cystectomy Undertaken with Curative Intent in Patients with Comorbidity and over 75 Years of Age. Urologia Internationalis, 2013, 90, 195-201.	1.3	20
52	A combined index to classify prognostic comorbidity in candidates for radical prostatectomy. BMC Urology, 2014, 14, 28.	1.4	20
53	Identifying Psychosocial Distress and Stressors Using Distress-screening Instruments in Patients With Localized and Advanced Penile Cancer. Clinical Genitourinary Cancer, 2017, 15, 605-609.	1.9	19
54	Hyperpolarization-Activated Cyclic Nucleotide-Gated Non-selective (HCN) Ion Channels Regulate Human and Murine Urinary Bladder Contractility. Frontiers in Physiology, 2018, 9, 753.	2.8	19

#	Article	IF	CITATIONS
55	A brief overview of the development of robot-assisted radical prostatectomy. Arab Journal of Urology Arab Association of Urology, 2018, 16, 293-296.	1.5	19
56	Management of Germ Cell Tumours of the Testes in Adult Patients: German Clinical Practice Guideline, PART II – Recommendations for the Treatment of Advanced, Recurrent, and Refractory Disease and Extragonadal and Sex Cord/Stromal Tumours and for the Management of Follow-Up, Toxicity, Quality of Life, Palliative Care, and Supportive Therapy. Urologia Internationalis, 2021, 105, 181-191.	1.3	19
57	Different HER2 Protein Expression Profiles Aid in the Histologic Differential Diagnosis Between Urothelial Carcinoma In Situ (CIS) and Non-CIS Conditions (Dysplasia and Reactive Atypia) of the Urinary Bladder Mucosa. American Journal of Clinical Pathology, 2011, 136, 881-888.	0.7	18
58	Treatment of Bone Metastases in Urologic Malignancies. Urologia Internationalis, 2014, 93, 249-256.	1.3	18
59	Effectiveness of Adjuvant Chemotherapy After Radical Cystectomy for Locally Advanced and/or Pelvic Lymph Node–Positive Muscle-invasive Urothelial Carcinoma of the Bladder: A Propensity Score–Weighted Competing Risks Analysis. European Urology Focus, 2018, 4, 252-259.	3.1	18
60	Analysis of psychosocial stress factors in patients with renal cancer. Therapeutic Advances in Urology, 2018, 10, 175-182.	2.0	18
61	Chronic Pelvic Painin Men. Urologia Internationalis, 2002, 68, 138-143.	1.3	17
62	Interaction Between Age and Comorbidity as Predictors of Mortality After Radical Prostatectomy. Journal of Urology, 2008, 179, 1823-1829.	0.4	15
63	Glansectomy as Primary Management of Penile Squamous Cell Carcinoma: An International Study Collaboration. Urology, 2017, 109, 140-144.	1.0	15
64	Upper Urinary Tract Tumors: Which Diagnostic Methods Are Needed?. Urologia Internationalis, 2017, 98, 304-311.	1.3	15
65	Optimising the selection of candidates for neoadjuvant chemotherapy amongst patients with nodeâ€positive penile squamous cell carcinoma. BJU International, 2020, 125, 867-875.	2.5	15
66	Loss of Mismatch-repair Protein Expression and Microsatellite Instability in Upper Tract Urothelial Carcinoma and Clinicopathologic Implications. Clinical Genitourinary Cancer, 2020, 18, e563-e572.	1.9	15
67	Comorbidity is poor predictor of survival in patients undergoing radical prostatectomy after 70 years of age. Urology, 2006, 68, 583-586.	1.0	14
68	Treatment of Locally Advanced Prostate Cancer – The Case for Radical Prostatectomy. Urologia Internationalis, 2006, 77, 193-199.	1.3	14
69	Which comorbidity classification best fits elderly candidates for radical prostatectomy?. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 461-467.	1.6	14
70	C-kit overexpression is not associated with KIT gene mutations in chromophobe renal cell carcinoma or renal oncocytoma. Pathology Research and Practice, 2014, 210, 521-525.	2.3	14
71	Diagnostic and prognostic value of bladder cancer-related transcript markers in urine. Journal of Cancer Research and Clinical Oncology, 2016, 142, 401-414.	2.5	14
72	Urinary transcript quantitation of CK20 and IGF2 for the non-invasive bladder cancer detection. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1757-1769.	2.5	14

#	Article	IF	CITATIONS
73	E2F1 Signalling is Predictive of Chemoresistance and Lymphogenic Metastasis in Penile Cancer: A Pilot Functional Study Reveals New Prognostic Biomarkers. European Urology Focus, 2018, 4, 599-607.	3.1	14
74	Cross-Sectional Patient-Reported Outcome Measuring of Health-Related Quality of Life With Establishment of Cancer- and Treatment-Specific Functional and Symptom Scales in Patients With Penile Cancer. Clinical Genitourinary Cancer, 2018, 16, e1215-e1220.	1.9	14
75	Age-dependent contribution of Rho kinase in carbachol-induced contraction of human detrusor smooth muscle in vitro. Acta Pharmacologica Sinica, 2014, 35, 74-81.	6.1	13
76	Nivolumab for the treatment of bladder cancer. Expert Opinion on Biological Therapy, 2017, 17, 1309-1315.	3.1	13
77	Rare ADAR and RNASEH2B variants and a type I interferon signature in glioma and prostate carcinoma risk and tumorigenesis. Acta Neuropathologica, 2017, 134, 905-922.	7.7	12
78	Predicting 90-day and long-term mortality in octogenarians undergoing radical cystectomy. BMC Urology, 2018, 18, 91.	1.4	12
79	A risk calculator predicting recurrence in lymph node metastatic penile cancer. BJU International, 2020, 126, 577-585.	2.5	12
80	Brachytherapy for Prostate Cancer. Urologia Internationalis, 1999, 63, 87-91.	1.3	11
81	Synthetic Nucleic Acids as Potential Therapeutic Tools for Treatment of Bladder Carcinoma. European Urology, 2007, 51, 315-327.	1.9	11
82	C-MET is expressed in the majority of penile squamous cell carcinomas and correlates with polysomy-7 but is not associated with MET oncogene amplification, pertinent histopathologic parameters, or with cancer-specific survival. Pathology Research and Practice, 2013, 209, 215-220.	2.3	11
83	Survival analysis in men undergoing radical prostatectomy at an age of 70 years or older. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 628-634.	1.6	10
84	Aggressive Angiomyxoma as a Rare Differential Diagnosis of Enlargement of the Scrotum. Clinical Genitourinary Cancer, 2016, 14, e237-e239.	1.9	9
85	Surgical resection of locally recurrent renal cell carcinoma after nephrectomy: Oncological outcome and predictors of survival. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 11.e1-11.e6.	1.6	9
86	Gender and Mortality after Radical Cystectomy: Competing Risk Analysis. Urologia Internationalis, 2018, 101, 293-299.	1.3	9
87	Inverse relationship of Rho kinase and myosin-light chain kinase expression in the aging human detrusor smooth muscle. BMC Urology, 2015, 15, 104.	1.4	8
88	Prediction of Locally Advanced Urothelial Carcinoma of the Bladder Using Clinical Parameters before Radical Cystectomy - A Prospective Multicenter Study. Urologia Internationalis, 2016, 96, 57-64.	1.3	8
89	Impact of photodynamic diagnosis-assisted transurethral resection of bladder tumors on the prognostic outcome after radical cystectomy: results from PROMETRICS 2011. World Journal of Urology, 2017, 35, 245-250.	2.2	8
90	Copy Number Alterations with Prognostic Potential in Clear Cell Renal Cell Carcinoma. Urologia Internationalis, 2018, 101, 417-424.	1.3	8

#	Article	IF	CITATIONS
91	Correlation of Pathological and Cytological-Cytometric Grading of Transitional Cell Carcinoma of the Urinary Tract. Urologia Internationalis, 2011, 86, 36-40.	1.3	7
92	P2Y receptor-mediated transient relaxation of rat longitudinal ileum preparations involves phospholipase C activation, intracellular Ca2+ release and SK channel activation. Acta Pharmacologica Sinica, 2016, 37, 617-628.	6.1	7
93	Critical evaluation of the PADUA score in a retrospective analysis of open partial nephrectomy. Turkish Journal of Urology, 2018, 44, 208-212.	1.3	7
94	Emerging apoptosis agonists for bladder cancer. Expert Opinion on Emerging Drugs, 2009, 14, 607-618.	2.4	6
95	Urinary immunocytology—Promise or nonseller? A review with an opinion. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 383-390.	1.6	6
96	Ageâ€related decrease of adenosineâ€mediated relaxation in rat detrusor is a result of A2B receptor downregulation. International Journal of Urology, 2015, 22, 322-329.	1.0	6
97	Psychological stress in geriatric patients with genito-urinary cancers. Journal of Geriatric Oncology, 2017, 8, 216-219.	1.0	6
98	Cure of Interstitial Cystitis and Non-Ulcerating Hunner's Ulcer by Cardinal/Uterosacral Ligament Repair. Urologia Internationalis, 2021, 105, 920-923.	1.3	6
99	How to Make the Diagnosis of Benign Prostatic Disease. European Urology Supplements, 2009, 8, 490-495.	0.1	5
100	Expression and clinicopathological correlations of retinoid acid receptor responder protein 1 in renal cell carcinomas. Biomarkers in Medicine, 2016, 10, 721-732.	1.4	5
101	Contemporary Treatment Patterns and Outcomes for Patients with Penile Squamous Cell Carcinoma: Identifying Management Gaps to Promote Multi-institutional Collaboration. European Urology Oncology, 2021, 4, 121-123.	5.4	5
102	Level of education and mortality after radical prostatectomy. Asian Journal of Andrology, 2017, 19, 173.	1.6	5
103	Changing comorbidity classification patterns at radical prostatectomy during a 10-year period. Urologic Oncology: Seminars and Original Investigations, 2007, 25, 26-31.	1.6	3
104	Comment on Di Silverio et al.: Neodajuvant Therapy with Sorafenib in Advanced Renal Cell Carcinoma with Vena Cava Extension Submitted to Radical Nephrectomy. Urologia Internationalis, 2008, 80, 454-454.	1.3	3
105	A New Neoadjuvant Chemotherapy Regimen for Penile Cancer with Nodal Metastases: A Step Forward. European Urology, 2009, 55, 552-553.	1.9	3
106	Reply to Kamran Zargar-Shoshtari, Pranav Sharma and Philippe E. Spiess' Letter to the Editor re: Oliver W. Hakenberg, Eva M. Compérat, Suks Minhas, Andrea Necchi, Chris Protzel, Nick Watkin. EAU Guidelines on Penile Cancer: 2014 Update. Eur Urol 2015;67:142–50. European Urology, 2015, 67, e111.	1.9	3
107	Lee mortality index as comorbidity measure in patients undergoing radical cystectomy. SpringerPlus, 2015, 4, 55.	1.2	3
108	Risk factors and survival outcomes for upstaging after inguinal lymph node dissection for cN1 penile squamous cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 838.e7-838.e13.	1.6	3

#	Article	IF	CITATIONS
109	Editorial Comment on: A Prospective Randomized Study Comparing Monopolar and Bipolar Transurethral Resection of Prostate Using Transurethral Resection in Saline (TURIS) System. European Urology, 2007, 52, 523.	1.9	2
110	Re: Niels M. Graafland, Joost A.P. Leijte, Renato A. Valdés Olmos, et al. Scanning with 18F-FDG-PET/CT for Detection of Pelvic Nodal Involvement in Inguinal Node-Positive Penile Carcinoma. Eur Urol 2009;56:339–45. European Urology, 2010, 57, e12-e13.	1.9	2
111	Re: Role of Human Papillomavirus in Penile Carcinomas Worldwide. European Urology, 2016, 70, 1078-1079.	1.9	1
112	Pathology, Molecular Biology, and Prognosis of Penile Squamous Cell Carcinoma: What Can We Learn from the Specimen?. European Urology Supplements, 2018, 17, 138-145.	0.1	1
113	Re: Differences in Survival Associated with Lymph Node Dissection in Patients with Invasive Penile Cancer: Results from the National Cancer Database. European Urology, 2018, 74, 678-679.	1.9	1
114	Effectiveness and Distribution of Testosterone Levels within First Year of Androgen Deprivation Therapy in a Real-World Setting: Results from the Non-Interventional German Cohort LEAN Study. Urologia Internationalis, 2021, 105, 436-445.	1.3	1
115	Ceruloplasmin expression in renal cell carcinoma correlates with higher-grade and shortened survival. Biomarkers in Medicine, 2021, 15, 841-850.	1.4	1
116	Re: Froehner M, Koch R, Litz RJ, Oehlschlaeger S, Hakenberg OW, Wirth MP, Feasibility and limitations of comorbidity measurement in patients undergoing radical prostatectomy. Eur Urol 2005;47:190–5. European Urology, 2005, 48, 169.	1.9	0
117	Reply to M.G. Clarke, R. MacDonagh. European Urology, 2005, 48, 170.	1.9	0
118	Re: Bladder Cancer Screening in a High Risk Asymptomatic Population Using a Point of Care Urine Based Protein Tumour Marker. European Urology, 2009, 56, 1087-1088.	1.9	0
119	Lymph Node Management in Penile Cancer. , 2019, , 833-843.		0
120	Lymph Node Management in Penile Cancer. , 2019, , 1-11.		0
121	Diagnosis and Staging in Penile Cancer. , 2019, , 1-8.		Ο
122	Flow-dependent differentiation of cultured adrenal cells under different stimuli. Cell and Tissue Research, 2021, 384, 325-331.	2.9	0
123	Urinmarker und zellbasierte Nachweisverfahren beim Urothelkarzinom. , 2007, , 135-155.		Ο
124	Chemotherapy in Penile Cancer. , 2014, , 199-214.		0
125	Peniskarzinom. , 2014, , 1-17.		0
126	Chemotherapy in Penile Cancer. , 2016, , 235-243.		0

0

#	Article	IF	CITATIONS
127	Urinmarker beim Blasenkarzinom. , 2018, , 135-152.		0

128 Diagnosis and Staging in Penile Cancer. , 2019, , 807-815.